BluePath Capital Management’s AbbVie ABBV Stock Holding History

BluePath Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.57M	Buy	6,233 +351	+6%	+$75.5K	0.86%	28
2026 Q1	$1.28M	Buy	5,882 +591	+11%	+$131K	0.88%	32
2025 Q4	$1.21M	Buy	5,291 +547	+12%	+$125K	0.82%	35
2025 Q3	$1.1M	Sell	4,744 -3,749	-44%	-$763K	0.8%	47
2025 Q2	$1.58M	Buy	8,493 +1,385	+19%	+$257K	1.39%	14
2025 Q1	$1.49M	Sell	7,108 -4,050	-36%	-$787K	1.55%	11
2024 Q4	$1.97M	Buy	11,158 +1,902	+21%	+$350K	1.06%	19
2024 Q3	$1.83M	Buy	9,256 +30	+0.3%	+$5.6K	1.13%	19
2024 Q2	$1.58M	Buy	9,226 +1,915	+26%	+$317K	1.11%	17
2024 Q1	$1.33M	Buy	7,311 +67	+0.9%	+$11.5K	1%	17
2023 Q4	$1.19M	Buy	7,244 +1,051	+17%	+$153K	1.02%	16
2023 Q3	$923K	Buy	+6,193	New	+$909K	0.85%	17

Other funds holding ABBV

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

HCM

Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

FWCM

Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return

BluePath Capital Management's ABBV Position: Q2 2026 in Review

BluePath Capital Management increased its AbbVie (ABBV) stake by 6% in Q2 2026, buying an estimated $75.5K and bringing the position to 6,233 shares worth $1.57M. The position accounts for 0.86% of the portfolio, ranked #28.

BluePath Capital Management first reported a position in ABBV in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.97M in Q4 2024. 1,476 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

BluePath Capital Management held 6,233 shares of AbbVie worth $1.57M as of Q2 2026.
BluePath Capital Management bought 351 AbbVie shares in Q2 2026, an estimated $75.5K.
AbbVie made up 0.86% of BluePath Capital Management's portfolio in Q2 2026, its #28 holding.
BluePath Capital Management first reported a position in AbbVie in Q3 2023 and has held it in 12 quarters since.
BluePath Capital Management's AbbVie position peaked at $1.97M in Q4 2024.
1,476 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on BluePath Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.